DuoGenic StemCells AAQS

Que fait DuoGenic StemCells ? DuoGenic StemCells Corp, listed under the ticker 7607.TWO with ISIN TW0007607004, is a company based in Taichung, Taiwan. It operates within the Health Care sector, specifically in the Life Sciences Tools & Services industry. The company made its initial public offering (IPO) on May 25, 2023. DuoGenic StemCells Corp provides biotechnology and medical care services, focusing on cell separator sets and culture media as part of its product offerings. Additionally, the company offers customized cell testing services, product certification, and technical consulting services on a consignment basis. Its headquarters are located in Taichung, Taiwan, and it maintains a website at https://www.dgsc.com.tw/ for further information. The company's business activities are centered around providing specialized services and products in the life sciences field, with an emphasis on cell-related technologies and medical applications. As a relatively new entrant to the public market, DuoGenic StemCells Corp is positioned to serve clients requiring advanced biotechnological solutions and medical care support. The company's services are designed to meet the needs of clients seeking expertise in cell-based applications and related medical services. Details regarding the company's founding year, specific executives, and financial figures are not provided in the available information. DuoGenic StemCells est l'une des entreprises les plus populaires sur Eulerpool.